Introduction {#s1}
============

Mutations in the *Crumbs Homolog 1* (*CRB1*) gene typically are associated with early-onset retinal degeneration (EORD) or Leber congenital amaurosis (LCA) with an autosomal recessive inheritance,[@i2164-2591-8-6-45-b01] the RP12 subform of retinitis pigmentosa (RP),[@i2164-2591-8-6-45-b02] but also with macular degeneration.[@i2164-2591-8-6-45-b03]

*CRB1* is a human homologue of the *Drosophila melanogaster* gene coding for protein crumbs (crb) expressed in the retina and brain.[@i2164-2591-8-6-45-b02] In *Drosophila,* the crb protein has been described to take part in a protein complex essential for proper polarity of peripheral neurons. In the mouse retina, *CRB1* is involved in photoreceptor morphogenesis, being localized in Mueller cells and photoreceptor inner segments---here mainly localized at the outer limiting membrane.[@i2164-2591-8-6-45-b04] Mammalian CRB proteins (CRBs) comprise several isoforms, with yet poorly defined individual functions. Although *CRB1* and its loss of function have been investigated in depth in mouse models, knowledge of the human CRB protein in the context of human retinal development and function remains scarce.[@i2164-2591-8-6-45-b05],[@i2164-2591-8-6-45-b06] Mammalian CRB is found in the outer limiting membrane, microvilli of Mueller cells, Henle\'s fibers of Mueller cells in close contact with photoreceptor cells as well as in their inner segments[@i2164-2591-8-6-45-b07] Although the exact role of *CRB1* in humans remains a matter of discussion, clinical findings in patients with *CRB1* mutations indicate that it is important for the morphogenesis and maturation of the retina.[@i2164-2591-8-6-45-b01],[@i2164-2591-8-6-45-b08] Interestingly, patients with retinal degenerations due to biallelic *CRB1* mutations have a relatively thick retina unlike other inherited retinal degenerations studied.[@i2164-2591-8-6-45-b08]

The proper assessment of the clinical phenotypes of patients with inherited retinal degenerations caused by *CRB1* mutations appears challenging, because these phenotypes present as variable, even for the same type of homozygous mutations.[@i2164-2591-8-6-45-b09] Nevertheless, some common typical patterns are identified. Patients most frequently present with LCA or an early-onset RP with the first symptoms in early childhood; the average age of first symptoms is 7 (range, 0--28 years).[@i2164-2591-8-6-45-b09],[@i2164-2591-8-6-45-b10] Specifically, a nummular pattern of retinal pigmentation rather than bone-spicula pigment deposits, thickening of the retina with abnormal layering resembling an immature human retina, hypermetropia, Coats-like exudations, and paravenous pigmentation progressing into chorioretinal atrophy are further morphologic aspects associated with the *CRB1* phenotype.[@i2164-2591-8-6-45-b01],[@i2164-2591-8-6-45-b08],[@i2164-2591-8-6-45-b09],[@i2164-2591-8-6-45-b11],[@i2164-2591-8-6-45-b12] Additionally, cystoid macular edema has been observed frequently in these patients. A distinct phenotype associated with *CRB1* mutations is cone-rod dystrophy with cystoid macular edema manifesting first in early childhood; the macular edema is pronounced and can be the first clinical finding in children mimicking other pediatric problems in ophthalmology, such as uveitis or X-linked retinoschisis.[@i2164-2591-8-6-45-b13][@i2164-2591-8-6-45-b14]--[@i2164-2591-8-6-45-b15] A recent study also reported a third phenotype of autosomal recessive *CRB1*-associated retinal degeneration due to the presence of the in-frame deletion variant c.498_506del, p.(Ile167_Gly169del) in the homozygous or compound heterozygous state, leading to macular dystrophy.[@i2164-2591-8-6-45-b03]

Due to early-onset of the degeneration, functional findings frequently are not measurable in young adulthood; subjective tests, such as visual fields, reveal concentric narrowing to less than 10° in early age. The best corrected visual acuity has been analyzed in the follow-ups of up to 45 years in 30 patients showing visual loss starting usually in the first decade with very variable progression rates involving temporary plateau phases.[@i2164-2591-8-6-45-b09] Despite the very different progression rates based on visual acuity measures interindividually, the progression shows a symmetrical pattern in both eyes of individual patients.[@i2164-2591-8-6-45-b09] Objective measures of the retinal function, such as responses from cones and rods, are not detectable on the full-field electroretinography in most patients.[@i2164-2591-8-6-45-b01],[@i2164-2591-8-6-45-b09],[@i2164-2591-8-6-45-b10]

To search for valid functional progression markers for the course of early-onset RP caused by *CRB1* mutations, we examined patients with standard functional retinal diagnostics and full-field stimulus threshold measurement, as well as pupillary responses to blue and red light.

Materials and Methods {#s2}
=====================

Clinical Investigations {#s2a}
-----------------------

Twelve patients (six females, six males; mean age, 37.8 ±14.3 years; range, 22--68 years) with early-onset RP caused by biallelic mutations in *CRB1* were examined at the Center for Ophthalmology, University of Tübingen, Germany.[@i2164-2591-8-6-45-b16] Two patients were excluded from the analysis group due to glaucoma, which could bias the results from functional diagnostics.

As the control group for pupillographic data, we used 10 healthy age-matched subjects (age, 36.68 ± 13.97) from a previously reported larger cohort.[@i2164-2591-8-6-45-b17]

All functional measurements were performed on both eyes. The research followed the tenets of the Declaration of Helsinki and informed consent was obtained from the subjects after explanation of the nature and possible consequences of the study. The protocol was approved by the Ethics Committee of the University Hospital of Tübingen.

The clinical examination included a detailed medical history, best corrected visual acuity (BCVA) testing using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts and the Berkeley residual vision test (BRVT)in the low and very low vision range,[@i2164-2591-8-6-45-b18] kinetic perimetry (Octopus 900; Haag-Streit International, Wedel, Germany), slit-lamp examination, fundus examination in mydriasis, full-field and multifocal electroretinography according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards with an Espion E2/E3 (Diagnosys LLC, Cambridge, UK), and dark-adapted full-field scotopic threshold with blue and red light (FST; Diagnosys LLC, Cambridge, UK) with 0 dB set to 0.01 cds/m^2^. The patients were dark-adapted for 20 minutes, based on ISCEV recommendations for scotopic full-field electroretinography (ERG). All ophthalmologic examinations were performed on both eyes.

For the FST examinations, the threshold values were averaged for both eyes per subject for the red and blue light measurements. Furthermore, the difference in the blue--red threshold as an indicator of rod-based vision[@i2164-2591-8-6-45-b19] was calculated for each eye and averaged per subject.

Pupillary responses to red (28 lux \[lx\]; peak, 606 nm; 0.4 μW/cm^2^/nm; full width at half maximum \[FWHM\], 12 nm) or blue (28 lx; peak, 426 nm; 19.5 μW/cm^2^/nm; FWHM, 21 nm) light were examined in a consensual manner in a completely darkened room without previous dark adaptation. The selected eye was stimulated with 28 lx bright light (red or blue, stimulus duration 4 seconds) using a color light emitting diode (LED) stimulator (CH Electronics, Bromley, UK). The pupil light reaction of the fellow eye was recorded using infrared pupillometry (Compact Integrated Pupillograph CiP; AMTech, Dossenheim, Germany) over a period of 16 seconds including a prestimulus time of 5 seconds. Changes in the pupil diameter were recorded at a sampling frequency of 250 Hz. All pupillograms were analyzed offline. Blink artifacts were removed semiautomatically using a customized software for analysis of pupillographic data written in MATLAB (MATLAB 2017b; MathWorks, Inc., Natick, MA). Read-out parameters were the maximal relative amplitude (MRA) and post illumination pupil response (PIPR). MRA (in percent) was calculated as MRA = 1 − the maximal pupil constriction amplitude / baseline pupil diameter. PIPR was calculated as a sum of the relative amplitudes from 2 seconds after stimulus to the end of the recording time (5 seconds after stimulus) and was normalized by the time. The difference in PIPR between blue and red light stimulation (blue--red) was calculated as an indicator for the inner retinal function (see prior report[@i2164-2591-8-6-45-b20] for detailed description).

Genetic Investigations {#s2b}
----------------------

Among the 10 patients enrolled in this study, one was analyzed using conventional Sanger sequencing of all coding exons of the *CRB1* gene. One patient was analyzed using a targeted panel-based next-generation sequencing approach designed at the Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.[@i2164-2591-8-6-45-b21] The remaining eight patients were analyzed using a panel-based sequencing approach in a diagnostic setting (Cegat GmbH and Praxis für Humangenetik, Tübingen, Germany). Variants were confirmed and family members were analyzed using conventional Sanger sequencing of the respective exons.

The potential pathogenicity of the missense changes identified in this study was assessed using four online prediction software tools, SIFT (available in the public domain at <http://sift.bii.a-star.edu.sg/>),[@i2164-2591-8-6-45-b22] PolyPhen-2 (available in the public domain at <http://genetics.bwh.harvard.edu/pph2/>),[@i2164-2591-8-6-45-b23] Mutation Taster (available in the public domain at [www.mutationtaster.org/](www.mutationtaster.org/)),[@i2164-2591-8-6-45-b24] and Provean (available in the public domain at <http://provean.jcvi.org/>).[@i2164-2591-8-6-45-b25]

Results {#s3}
=======

Clinical Findings {#s3a}
-----------------

Ten patients (5 males, 5 females; mean age, 34.4 ± 11.9 years; range 22--56 years) with two *CRB1* variants were included in the data analysis. Disease duration varied between 17 and 56 years (average, 32 ± 12.13 years). Age at first symptom onset was within the first 6 years in all patients (average age, 2.4 years) based on reports from the medical history. The clinical findings are summarized in [Table 1](#i2164-2591-8-6-45-t01){ref-type="table"}.

###### 

Overview of the Clinical Findings in Patients With Early-Onset RP Caused by CRB1 Mutations

                              *CRB1* Variants                    Reference (PMID)   MAF           Segregation Performed    Sex  Age at Onset   Age at Visit   Disease Duration
  --------------------------- ---------------------------------- ------------------ ------------- ----------------------- ----- -------------- -------------- ------------------
  CRB1-01                     c.2230C\>T/*P*.R744\* hom          25323024           0.00001221    Yes                       M   0              24             24
  CRB1-02                     c.2308G\>A/*P*.G770S hom           27113771           0.00002036    No                        F   6              47             41
  CRB1-04                     c.803_806del/*P*.S268Nfs\*33 het   This study         None          Yes                       F   0              34             34
  c.2234C\>T/*P*.T745M het    10508521                           0.00006506                                                                                   
  CRB1-05                     c.733del/*P*.A245Pfs\*57 het       This study         None          Yes                       F   5              26             21
  c.1914G\>T/*P*.S638S het                                                                                                                                    
  CRB1-09                     c.407G\>A/*P*.C136Y het            26766544           0.000004079   Yes                       F   4              48             44
  c.1465G\>T/*P*.E489\* het                                      None                                                                                         
  CRB1-10                     c.2248G\>A/*P*.G750S hom           23591405           None          Yes                       F   0              56             56
  CRB1-12                     c.2498G\>A/*P*.G833D het           23077403           None          Yes                       M   2              22             20
  c.3442T\>C/*P*.C1148R het   24618324                                                                                                                        
  CRB1-13                     c.506del/*P*.G169Vfs\*37 het       23591405           0.000008127   Yes                       M   1              40             39
  c.3086T\>A/*P*.V1029E het   This study                         None                                                                                         
  CRB1-15                     c.2843G\>A/*P*.C948Y hom           10508521           0.0002027     Yes                       M   1              25             24
  CRB1-16                     c.2843G\>A/*P*.C948Y hom           10508521           0.0002027     Yes                       M   5              22             17

Age at onset of the first symptoms, age at visit and disease duration (defined as the difference of the age at visit and the age of first symptoms) are expressed in years. Hom, homozygous; het, heterozygous; PMID, PubMed ID; MAF, minor allele frequency; R, right; L, left; n.m., not measurable; FC, finger counting; HM, hand movement perception; LP, light perception without light projection; f, female; m, male.

###### 

Extended

            BCVA (decimal)   Visual Field   Full Field ERG                      mfERG   FST in dB (0 dB = 0.01 cd/m^2^)  Pupillography                           
  --------- ---------------- -------------- ---------------------------------- ------- --------------------------------- --------------- ------- ------- ------- ------------------
  CRB1-01   FC               FC             n.m.                                n.m.                 n.m.                −2.3            −4.5    −28.0   −29.0   Performed
  CRB1-02   LP               LP             n.m.                                n.m.                 n.m.                −0.5            −1.2    −8.0    −12.0   Performed
  CRB1-04   0.3              0.4            10°                                 n.m.                 n.m.                −11.0           −12.6   −11.9   −17.0   Performed
  CRB1-05   0.5              0.1            \<5° central and periph. Islands    n.m.                 n.m.                −9.6            −12.9   −31.6   −37.7   Performed
  CRB1-09   LP               0.025          n.m.                                n.m.                 n.m.                −2.6            −3.7    −13.9   −16.9   Performed
  CRB1-10   LP               LP             n.m.                                n.m.                 n.m.                n.m.            n.m.    n.m.    n.m.    n.m. (nystagmus)
  CRB1-12   0.01             0.025          L \<5° central                      n.m.                 n.m.                −7.6            −10.8   −30.3   −35.1   Performed
  CRB1-13   HM               0.005          n.m.                                n.m.                 n.m.                0.8             1.5     2.5     0.4     n.m. (nystagmus)
  CRB1-15   LP               LP             n.m.                                n.m.                 n.m.                −1.8            −3.3    −16.3   −19.8   Performed
  CRB1-16   0.05             0.25           Ring scotoma                        n.m.                 n.m.                −16.7           −16.5   −40.2   −39.7   Performed

Visual acuity was measurable in six patients; in two of them, only one eye was measurable with the second eye having only light (CRB1-09) or hand motion (CRB1-13) perception. After converting the BCVA into logMAR values and estimating the logMAR of low-vision BCVA based on the previous research of Lange et al.,[@i2164-2591-8-6-45-b26] we found a significant correlation in BCVA with the thresholds for red FST (*r* = 0.89, *P* = 0.008). Significant correlations were not found in BCVA for the blue FST threshold or for the pupillographic results.

The visual field was measurable in only three patients who had the shortest disease duration at presentation. They showed a classic ring scotoma (with an irregular central visual field of 10°--20°) for the patient with the shortest disease duration of 17 years, and a visual field constriction to \<5° in two patients with disease duration of 20 and 21 years, respectively.

Full-field and multifocal electroretinography according to ISCEV standards showed no measurable responses in all patients. Full-field scotopic threshold to blue and red light was measurable in all patients except the one with the longest disease duration of 56 years (the patient could not see any light in the FST test). Pupillary responses were measurable in eight patients; the reason for nonrecordable pupillary responses in the two remaining patients was severe nystagmus. Baseline pupil sizes were 5.4 ± 0.6 and 5.5 ± 0.68 mm for red and blue light responses, respectively, in the patient group and 7.0 ± 0.47 and 6.9 ± 0.53 mm, respectively, in the control group. The pupil baselines were significantly smaller in patients than in the controls for red and blue light conditions (*P* \< 0.001).

Correlations With Disease Duration {#s3b}
----------------------------------

Visual acuity was not measurable in all patients. Moreover, CRB1-09, CRB1-12, and CRB1-13 performed the BCVA test using eccentric vision. The few obtained values showed no correlation with disease duration or age (*r* = −0.25, *P* = 0.6; data not shown). Visual field was measurable in only three patients. The thresholds for blue light showed a strong correlation with disease duration (*r* = 0.87), whereas the thresholds for red light showed a weaker correlation (*r* = 0.65; [Fig. 1A](#i2164-2591-8-6-45-f01){ref-type="fig"}). Both thresholds rose during the disease progression. The correlation was weaker if the FST values were correlated with age instead of disease duration (*r* = 0.77 for blue light, *r* = 0.57 for red light, data not shown).

![Correlation of the FST thresholds with the individual disease duration. (A) Correlation of the FST threshold values in dB on the y-axis (as defined from the baseline of 0 dB = 0.01 cd/m^2^) with disease duration in years on the x-axis. Values for the FST test with blue and red light are shown in the corresponding colors. (B) Correlation of the FST blue--red threshold difference in dB averaged from both eyes per subject with disease duration in years.](i2164-2591-8-6-45-f01){#i2164-2591-8-6-45-f01}

For the blue--red difference in the FST threshold, there was a clear increase with disease duration with a correlation of *r* = 0.8 ([Fig. 1B](#i2164-2591-8-6-45-f01){ref-type="fig"}), whereas only patients in the late stages beyond 30 years of disease duration approached the blue--red difference of zero indicating a pure cone-based vision. The blue--red differences correlated less strongly with age (*r* = 0.71, data not shown).

The MRAs as well as the PIPRs for red and blue light were averaged over both eyes for each patient. The MRA showed a small reduction with the disease duration in either color with a low correlation (*r* = −0.55 for blue, *r* = −0.3 for red); however, this correlation did not reach statistical significance ([Fig. 2](#i2164-2591-8-6-45-f02){ref-type="fig"}). The correlation did not change relevantly if MRAs were correlated with age instead of disease duration (*r* = −0.6 for blue, *r* = −0.22 for red; data not here).

![Correlation of the MRA (%; y-axis) with disease duration (years; x-axis). Values for the tests with blue and red light are shown in the corresponding colors.](i2164-2591-8-6-45-f02){#i2164-2591-8-6-45-f02}

The difference in the PIPR between blue and red stimulation showed no correlation either with disease duration or age (*r* = −0.05 for disease duration \[[Fig. 3](#i2164-2591-8-6-45-f03){ref-type="fig"}\] and *r* = −0.2 for age \[data not shown\]).

![Correlation of the PIPR difference (blue--red) with disease duration.](i2164-2591-8-6-45-f03){#i2164-2591-8-6-45-f03}

Comparison of the Pupil Response Results between Patients With Biallelic *CRB1* Variants and Healthy Eyes {#s3c}
---------------------------------------------------------------------------------------------------------

Average pupil response curves differed from the age-matched norm values for blue and red stimuli ([Fig. 4](#i2164-2591-8-6-45-f04){ref-type="fig"}). The maximal relative constriction amplitudes were reduced for red and blue light.

![Averaged pupillary response curves for healthy eyes (full line) and CRB1 patients (dashed line) for blue and red stimuli (stimulus duration 4 seconds from time point 5--9 seconds).](i2164-2591-8-6-45-f04){#i2164-2591-8-6-45-f04}

MRAs were significantly smaller in the *CRB1* cohort than in the normal age-matched population (*P* \< 0.001, [Fig. 5](#i2164-2591-8-6-45-f05){ref-type="fig"}).

![MRAs for healthy age-matched control eyes (light colored bars with standard deviations) and patients carrying CRB1 mutations (dark colored bars with standard deviations) to red and blue full-field stimulation differ significantly (P \< 0.001).](i2164-2591-8-6-45-f05){#i2164-2591-8-6-45-f05}

The difference PIPR blue -- PIPR red as a parameter of the inner retinal function was significantly increased for the *CRB1* patient group compared to that in age-matched healthy controls (*P* = 0.003, [Fig. 6](#i2164-2591-8-6-45-f06){ref-type="fig"}).

![The difference in the PIPR between blue and red stimulation (blue--red) was significantly increased in the cohort with CRB1 mutations (black bar with standard deviation) compared to that in the age-matched normal population (gray bar with standard deviation).](i2164-2591-8-6-45-f06){#i2164-2591-8-6-45-f06}

Genetic Findings {#s3d}
----------------

All patients in our cohort carried biallelic putative pathogenic variants in the *CRB1* gene. The genotypes are listed in [Table 1](#i2164-2591-8-6-45-t01){ref-type="table"}, and the pathogenicity predictions for the missense variants are shown in [Table 2](#i2164-2591-8-6-45-t03){ref-type="table"}. Segregation analysis was not possible in patient CRB1-02. Therefore biallelism could not be formally proven in this case. We considered all variants in [Table 2](#i2164-2591-8-6-45-t03){ref-type="table"} to be pathogenic, except for the p.S638S variant. This variant was seen in the compound heterozygous state with a 1-bp deletion in patient CRB1-05. In silico analysis of the p.S638S variant using two splice site prediction algorithms embedded in the Human Splicing Finder version 3.1[@i2164-2591-8-6-45-b27] revealed no significant difference between mutant and reference sequence. However, since the variant is not listed in the Genome Aggregation Database (gnomAD) Version r2.0.2,[@i2164-2591-8-6-45-b28] it seems to be extremely rare, if not private, and might execute a splicing defect that could not be predicted by the algorithms we used. Because the counter allele in patient CRB1-05 is a true loss--of-function allele, the contribution of a hypomorphic allele would be sufficient to explain the phenotype.

###### 

Assessment of the Pathogenicity of the Missense Variants Identified in This Study

  Variant                 Mutation Taster          Polyphen                   SIFT             Provean
  ----------------------- ------------------------ -------------------------- ---------------- ----------------------
  c.407G\>A/*P*.C136Y     Disease causing (0.99)   Probably damaging (1.0)    Damaging (0.0)   Deleterious (−8.26)
  c.2234C\>T/*P*.T745M    Disease causing (0.99)   Probably damaging (1.0)    Damaging (0.0)   Deleterious (−4.85)
  c.2248G\>A/*P*.G750S    Disease causing (0.99)   Probably damaging (0.99)   Damaging (0.0)   Deleterious (−5.47)
  c.2308G\>A/*P*.G770S    Disease causing (0.99)   Probably damaging (1.0)    Damaging (0.0)   Deleterious (−5.48)
  c.2498G\>A/*P*.G833D    Disease causing (0.99)   Probably damaging (0.99)   Damaging (0.0)   Deleterious (−6.34)
  c.2843G\>A/*P*.C948Y    Disease causing (0.99)   Probably damaging (0.99)   Damaging (0.0)   Deleterious (−9.66)
  c.3086T\>A/*P*.V1029E   Disease causing (0.99)   Probably damaging (0.99)   Damaging (0.0)   Deleterious (−5.21)
  c.3442T\>C/*P*.C1148R   Disease causing (0.99)   Probably damaging (1.0)    Damaging (0.0)   Deleterious (−10.90)

Discussion {#s4}
==========

RP caused by autosomal recessive *CRB1* mutations typically is an early-onset disease with its first manifestation before school age. As usual with EORDs, progress often is more rapid than in most retinal degeneration cases with later onset; thus, classical clinical follow-up functional diagnostics, such as perimetry or electroretinography, are no more reliably measurable in young adult years.[@i2164-2591-8-6-45-b01],[@i2164-2591-8-6-45-b09],[@i2164-2591-8-6-45-b10]

In this study, we included only patients with early-onset RP due to biallelic *CRB1* mutations into the analysis. Other phenotypes, such as cone or cone-rod degenerations with early macular edema,[@i2164-2591-8-6-45-b13],[@i2164-2591-8-6-45-b14] or macular degeneration due to *CRB1* mutations,[@i2164-2591-8-6-45-b03] were not part of this cohort because they present a different subtype of the *CRB1* phenotype.

In our cohort, the four patients with the shortest disease duration (17, 20, 21, and 34 years) had a measurable visual field, whereas the largest visual field area belonged to the one with the shortest disease duration of 17 years. Although these findings confirmed that perimetry is a valid clinical progression marker in RP, its clinical relevance disappears in the early adult age in the cohort with *CRB1* mutations due to the fast progression. Similarly, the few values of measurable visual acuity did not correlate strongly with disease duration, but this result might be due to underpowered data (only six patients); the remaining patients did not have a reliably measurable visual acuity.

In general, functional follow ups in the late stages of retinal degenerations are a challenge for functional diagnostics. Following outer retinal degeneration, functionality of the inner retina is not well accessible for functional tests. This becomes a challenge for novel therapies for inherited retinal degenerations.[@i2164-2591-8-6-45-b29][@i2164-2591-8-6-45-b30][@i2164-2591-8-6-45-b31]--[@i2164-2591-8-6-45-b32] We showed here that the responses to blue light measured by FST testing may be a valid marker for functionality decline and disease progression in patients with *CRB1* variants in stages up to more than 40 years of disease duration. In the oldest patient of 56 years, even this subjective dark-adapted blue light threshold by FST could no longer be measured due to extremely low retinal sensitivity: the patient could not see any light in the test setting. We showed that the subjective test of the dark-adapted threshold to blue light correlates better with the individual disease duration than with age, indicating that the slightly different onset of the symptoms might be more relevant for progression than the objective age. The difference in the blue and red thresholds is a parameter indicating whether rod-based, dark-adapted vision is available: a difference that is significantly different from zero is a sign of rod-based vision; differences below 5 dB prove a cone-driven function; if the difference is 20 dB or more, it is rod-driven.[@i2164-2591-8-6-45-b19] In this cohort, rod-based vision was clearly available for the younger part of the cohort (with disease duration up to 24 years; these patients were younger than 27 years), patients a with disease duration of more than 30 years approached values around zero. This shows that some residual rod function is present in the retina in later stages of *CRB1*--associated RP even as late as 30 years after the first symptom onset. Moreover, these results showed that the FST measurement could provide measurable outcomes in patients with no remaining visual field.

An additional test that can provide measurable results in the late stages of RP is analyzing pupil responses to full-field stimulation with blue or red light.[@i2164-2591-8-6-45-b20] These responses are objective, in contrast to FST responses, where the patient is asked to respond by the trigger button. The pupil responses provide some more insight into the progression of retinal degeneration. An important, although expected finding is the reduction of the MRA for red and blue full-field stimulation in patients with *CRB1* variants compared to age-matched normal eyes, a finding that is consistent with our previous examinations of RP patients independent of gene mutation[@i2164-2591-8-6-45-b17] and the results from other groups.[@i2164-2591-8-6-45-b33][@i2164-2591-8-6-45-b34]--[@i2164-2591-8-6-45-b35] This reduction of the pupil responses is a result of the degeneration of the photoreceptor layer, and possibly also the partial degeneration of ganglion cells. We could not observe the same strong correlation of the functional decline as in the FST subjective dark adaptation thresholds over the disease duration.

In general, the pupil response is a combination of multiple contributions from cones, rods and melanopsin-mediated direct activation of intrinsically photosensitive retinal ganglion cells (ipRGCs). Thus, even when most photoreceptors are degenerated, there is a residual pupil response driven by the ipRGC activity. Similar to a previously reported cohort of patients with LCA and EORD carrying *RPE65* variants,[@i2164-2591-8-6-45-b35] the PIPR---a sign of ipRGCs activity---was larger in the *CRB1* than in the control groups. This can be interpreted in several ways. First, the inner retinal function remains preserved (as far as ipRGC signaling is concerned). Secondly, the lack of inhibitory signals from blue cones may even increase this parameter. This was already speculated in previous publications.[@i2164-2591-8-6-45-b17],[@i2164-2591-8-6-45-b20] Additionally, this lack of inhibitory signal could explain the observed difference between the baseline pupil size between controls and *CRB1* patients. Thus, because several factors exist with possibly opposite effects on the amplitude of pupil responses, it is not surprising that we could not find a linear correlation between the disease duration and MRA.

We observed no change in of the PIPR difference (blue--red) over the disease duration. We speculated that the function of inner retina, despite some morphologic changes, is preserved during disease progression. This information is critically important to implement new emerging therapeutic approaches. In patients with *CRB1* mutations, in particular, the inner retina is thickened compared to the healthy retina.[@i2164-2591-8-6-45-b08] It has been proposed that this thickening may reflect a functionality loss, because the thickened inner retina resembles an immature tissue. However, a good retinal function in the early years of most patients as well as our PIPR results indicated that this may not necessarily be true for the remaining inner retina even after progressed outer retinal degeneration. The OCT imaging showed *CRB1*-associated thickening of the retina in all patients, as reported in the literature.

Interestingly, the maximal relative pupil constriction amplitude to cone-favoring stimuli (red stimuli) showed no dependence on the disease duration. However, we found a clear difference between the groups carrying *CRB1* variants and healthy controls in this value; namely, a reduction of the pupil responses in the patient cohort. This indicated that this change already has been present in the early phase of the disease and remained relatively stable. We could speculate that the pathologic morphogenesis and maturation of the retina in the *CRB1* phenotype[@i2164-2591-8-6-45-b01],[@i2164-2591-8-6-45-b08] leads to an early functional problem of the cones that does not deteriorate rapidly over the life decades. However, because our population included patients with \>10 years disease duration, this assumption is only speculative. Additionally, the cross-sectional nature of this study presents a limiting factor in predicting the functional progression in early-onset RP caused by biallelic *CRB1* mutations.

An interesting finding in this cohort is the strong correlation of the visual acuity with the red FST thresholds. This correlation must be considered cautiously, because the very low values of the BCVA are not reliably measurable and were gained via different test methods: Snellen acuity or BRVT or via logMAR estimation based on previous publications.[@i2164-2591-8-6-45-b26]

Two of our patients with an EORD due to the *CRB1* genotype were excluded from the analysis due to glaucoma. Scant literature supports a glaucoma association with the *CRB1* gene. Henderson et al.[@i2164-2591-8-6-45-b36] described that two of 41 patients with a *CRB1* retinal dystrophy had seclusio pupillae and secondary glaucoma due to peripheral retinal telangiectasia. Our patient CRB1-06 suffered angle-closure glaucoma in both eyes at the age of 56 years due to cataract. Patient CRB1-14 had also angle-closure glaucoma on both eyes at the age of 40 years. This patient also presented with corneal opacities and suspected keratoconus. Because glaucoma can change retinal function, we excluded these patients from analysis because we had insufficient evidence to state that glaucoma would be a feature strongly associated with the *CRB1* phenotype.

Conclusions {#s5}
===========

Full-field stimulus threshold with blue light as well as the blue--red difference of the thresholds have the potential to be a valid clinical progression marker in early-onset RP caused by biallelic *CRB1* mutations even in late stages with no detectable visual field. The pupil responses to full-field chromatic stimuli show significant differences to those in a normal population; the remaining responses, although reduced, indicated a partially preserved inner retinal function, despite severe photoreceptor dysfunction. Confirmation of these results and conclusions is necessary through longitudinal studies.
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